The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
New publication: Performance Indicators in Breast Cancer Screening in the European Union: A Comparison Across Countries of Screen Positivity and Detection Rates13/03/2020
This is the first publication presenting adjusted breast cancer screening positivity and detection rates across Europe using data from the Second EU Screening Report. We documented large variability by country in detection rates at subsequent screening tests, likely due to differences in background risk, awareness of the target populations, and different screening protocols and organization. Periodic reporting of performance indicators permits comparisons and monitoring of the impact of screening programmes in EU-Member States. View the article.
Webinar: CanScreen5 in Latin America region06/03/2020
The screening group organized in collaboration with Silvana Luciana from PAHO a virtual webinar with representatives from 12 Latin American countries (Argentina, Brazil, Chile, Colombia, Costa Rica, El Salvador, Honduras, Mexico, Nicaragua, Panama, Paraguay and Peru) to discuss the implementation of the CanScreen5 project and to study the barriers to cancer screening in the region.
Meeting: Developing the new guidelines for cervical cancer screening and treatment and Methodology Meeting, Montreux, Switzerland02/03/2020 – 05/03/2020
Dr Partha Basu and Catherine Sauvaget participated to the WHO meeting of the WHO-Guideline Development Group on “Cervical Cancer Screening Recommendations”.
Video: Population-based trials on the safety, immunogenicity, efficacy and impact of human papillomavirus (HPV) vaccination, by professor Matti Lehtinen of the Karolinska Institutet (Stockholm, Sweden) and the Finnish Institute for Health and Welfare (Helsinki, Finland)04/03/2020
Professor Matti Lehtinen of the Karolinska Institutet (Stockholm, Sweden) and the Finnish Institute for Health and Welfare (Helsinki, Finland) visited the International Agency for Research on Cancer (IARC) on 3 March 2020 and presented a seminar on “Population-based trials on the safety, immunogenicity, efficacy and impact of human papillomavirus (HPV) vaccination.” Watch video.
|Armaroli P., Riggi E., Basu P., Anttila A., Ponti A., Carvalho A.L., Dillner J., Elfstrom M.K., Giordano L., Lonnberg S., Ronco G., Senore C., Soerjomataram I., Tomatis M., Vale D.B., Jarm K., Sankaranarayanan R., Segnan N. Performance Indicators in Breast Cancer Screening in the European Union: A Comparison Across Countries of Screen Positivity and Detection Rates. Int J Cancer. 2020 Mar 11.|
|Mariz F.C., Bender N., Anantharaman D., Basu P., Bhatla N., Pillai M.R., Prabhu P.R., Sankaranarayanan R., Eriksson T., Pawlita M., Prager K., Sehr P., Waterboer T., Muller M., Lehtinen M. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020 Feb 14;5:14.|
|Ponti A., Basu P., Ritchie D., Anttila A., Carvalho A.L., Senore C., Mallafre-Larrosa M., Piccinelli C., Ronco G., Soerjomataram I., Primic-Žakelj M., Dillner J., Elfstrom M.K., Lonnberg S., Vale D.B., Tomatis M., Armaroli P., Giordano L., Sankaranarayanan R., Segnan N. Key issues that need to be considered while revising the current Annex of the European Council Recommendation (2003) on cancer screening. Int J Cancer. 2020 Jan 22.|